Cardiovascular cryoablation tech developer Adagio Medical has raised approximately $7 million in a new round of equity and options financing, according to a recently posted SEC filing.
The company is looking to raise an additional $13 million, which would bring the total raised up to $20 million, according to the filing.
Adagio Medical is developing and producing ultra-low temperature cryoablation catheters intended to create endocardial, continuous, transmural lesions on the heart, according to the company’s website.
Money in the round came from seven unnamed sources, with the first date of sale noted as having occurred on February 26, according to the SEC filing.
Last December, Adagio Medical said that it launched its One Shot+ cryoablation catheter, and that the first patient has been treated with the device.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.